Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019

Igbinosa, Irogue; Miller, Sarah E.; Bianco, Katherine; Nelson, Joanna; Kappagoda, Shanthi; Blackburn, Brian G.; Grant, Philip; Subramanian, Aruna; Lyell, Deirdre J.; El‐Sayed, Yasser Y.; Aziz, Najib

doi:10.1016/j.ajog.2020.08.001

Cited by 37 publications

(62 citation statements)

References 5 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A case series of three pregnant patients with severe COVID-19 pneumonia who required supplemental oxygen demonstrated resolution of this requirement after initiation of remdesivir. In this series, remdesivir was well tolerated overall, with only one patient experiencing elevation in the levels of liver function enzymes that required discontinuation of remdesivir ( 45 ). Another report of 67 pregnant patients who received remdesivir through the compassionate use program demonstrated that 93% recovered within 28 days.…”

Section: Special Populationsmentioning

confidence: 81%

New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19

Aleissa

Silverman

Acosta

et al. 2020

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with COVID-19. Remdesivir is the prodrug of an adenosine analogue that inhibits viral replication of several RNA virus families including Coronaviridae. Preclinical data in animal models of coronavirus diseases, including COVID-19, have demonstrated that early treatment with remdesivir leads to improved survival, decreased lung injury and decreased quantification of viral RNA. Recent clinical data have demonstrated the clinical activity of remdesivir in terms faster time to recovery in patients with severe COVID-19 and higher odds of improved clinical status in patients with moderate COVID-19. Clinical trials published to date are presented and appraised. Remdesivir's potential benefits and its favorable adverse event profile make it an option for the treatment of COVID-19. This article examines the available literature describing remdesivir's pharmacology, pharmacokinetics, and preclinical and clinical data.

show abstract

Section: Special Populationsmentioning

confidence: 81%

New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19

Aleissa

Silverman

Acosta

et al. 2020

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…The RT‐PCR study of nasopharyngeal and oropharyngeal samples obtained from all neonates were negative on the first, third, and 14th day of life. One of the samples of breast milk obtained from the mothers was positive for SARS‐CoV‐2 15 …”

Section: Resultsmentioning

confidence: 99%

“…Venous thromboembolism prophylaxis is recommended for hospitalized pregnant women with COVID‐19 14 . Although no fetal toxicity was reported in the use of remdesivir against the Ebola and Marburg viruses, knowledge is limited on this drug and it is therefore not recommended for pregnant and breastfeeding women with COVID‐19 infection 15 . Convalescent plasma, tocilizumab, and recombinant human IL‐1 receptor antagonist were rarely used in pregnant women 13 .…”

Section: Discussionmentioning

confidence: 99%

Updated experience of a tertiary pandemic center on 533 pregnant women with COVID‐19 infection: A prospective cohort study from Turkey

Şahın

Tanaçan

Erol

et al. 2020

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…[ 24 ] Several cases showed that remdesivir might be effective and safe for the treatment of severe COVID‐19 in pregnancy. [ 25–27 ]…”

Section: Treatment Of Covid‐19 In Pregnant Womenmentioning

confidence: 99%

Management of Pregnancy during the COVID‐19 Pandemic

Fang

Wang

et al. 2020

Global Challenges

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19) is spreading worldwide. All aspects of pregnancy management from conception to delivery to puerperium as risks facing newborns are herein, reviewed. Maternal home management and prenatal care management protection, delivery timing or mode selection, delivery process management, and subsequent puerperal protection are crucial. In this Review, the features and treatment strategies, especially emphasizing the safety of antiviral drugs for pregnant women, the wearing of face masks, and practicing of personal hygiene (e.g., handwashing, disinfection, home cleaning, and ventilation) are reviewed as essential protective measures. It is recommended to provide online consultation, telemedicine, and remote fetal heart rate monitoring and set the flow point for prenatal examination to encourage prenatal examination at home or postponing examinations (except nuchal translucency at 11‐13+6 weeks, Oscar Test at 16 weeks, and fetal ultrasound at 20–24 weeks). It is shown that the precise formulation of follow‐up strategies for pregnant women with COVID‐19 is necessary.

show abstract

Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019

Cited by 37 publications

References 5 publications

New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19

New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19

Updated experience of a tertiary pandemic center on 533 pregnant women with COVID‐19 infection: A prospective cohort study from Turkey

Management of Pregnancy during the COVID‐19 Pandemic

Contact Info

Product

Resources

About